Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. The claims align with aspects of the Cream label (topical use for cutaneous infections, non-systemic use, contraindications, minimal systemic absorption, storage considerations), but numerous claims reference oral suspension dosing, oral indications, and pediatric use that are not supported by the provided Cream label. The mixture of topical-label content with non-applicable suspension indications reduces overall alignment.
Category Scores
Accurate Statements
Topical treatment for cutaneous infections (not the oral suspension).
INDICATIONS AND USAGE
Note: It is not an antifungal for systemic infections.
INDICATIONS AND USAGE
Contraindication: Known hypersensitivity to nystatin or any component of the suspension.
CONTRAINDICATIONS
Drug interactions: Minimal systemic absorption → few systemic interactions.
PHARMACOKINETICS
Unsupported Statements
Nystatin is a polyene antifungal.
LABEL DOES NOT STATE CLASSIFICATION
Indication: Oral candidiasis (thrush) in children and adults.
Label indicates Nystatin Cream USP is not indicated for oral use.
Indication: Fungal infections of the mouth and pharynx.
Cream label does not indicate oral/oropharyngeal use.
Dosage (adults & children > 12 months, oral suspension): 5 mL (≈ 500,000 U) 3–4×/day; Swish in mouth, then swallow.
Label does not provide oral suspension dosing for Cream.
Dosage (children 6–12 months, oral suspension): 2.5 mL (≈ 250,000 U) 3–4×/day; Adjust according to weight.
Label does not provide oral suspension dosing for Cream.
Course length: 7–14 days (extend if symptoms persist).
Label for Cream does not specify course length for oral suspension; not applicable to Cream label.
Tolerability: Mild GI upset is common; advise patient to avoid eating/drinking 30 min before next dose.
Label does not provide this dosing guidance for topical Cream.
Pediatrics (<6 months): Not recommended; limited data.
Pediatric Use: Safety and effectiveness established from birth to 16 years.
Holistic administration instructions (shake well, measure with cup, swish 30–60 s, avoid food/drink 30 min after) for suspension.
Label content provided here pertains to Cream and does not include suspension-directed instructions.
Contradictions
Low
AI Statement
Indication: Oral candidiasis (thrush) in children and adults.
Label Reference
INDICATIONS AND USAGE
Important Omissions
Pediatric dosing specifics for ages outside the established label (birth to 16 years) as they pertain to the Cream product; oral suspension dosing details; explicit storage and shelf-life for the Cream product.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label indicates topical use with minimal systemic absorption and limited systemic interactions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Formulation mismatch: claims reference oral suspension/indications not supported by the Cream label; ensure claims align with product form.
Suggested Improvement
Limit AI-generated claims to the Cream label indications and administration; clearly separate any claims pertaining to oral suspension if the label is for a different product; include suspension-specific dosing only if applicable to the labeled product.